SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: E. Todd Phillips who wrote (551)4/5/1998 4:28:00 PM
From: yosi s  Read Replies (1) | Respond to of 1491
 
We are getting ahead of ourselves in this thread.

For pars tamoxiphen analoge to get designation for breast cancer prevention will take long years.

They first got to get through phase 1
Yes it has that potential.

But right now HU211 is in late phase 2 (2-3 yrs ahead of tamoxiphen).
yet hu211 is completely discounted in the value of PARS.
If PARS was Merck yes than credit be there.

But all in all Pars version of tamoxiphen may have that indication if it is effective and safer as theoretically it seems.



To: E. Todd Phillips who wrote (551)4/5/1998 5:47:00 PM
From: george m. miller  Read Replies (1) | Respond to of 1491
 
Todd.. Can you supply address of Pharmos web site.
Thanks



To: E. Todd Phillips who wrote (551)4/6/1998 7:22:00 PM
From: FTJoe  Read Replies (2) | Respond to of 1491
 
To anyone - I was listening to the tamoxifen report with half an ear and missed a mentioned product name. Another product with supposedly no side effects and 74% reduction in breast cancer. Started with an R, anyone hear the drug name and/or know of the company developing it?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News